Article Text

Download PDFPDF
A prospective study of mifepristone and unlimited dosing of sublingual misoprostol for termination of second-trimester pregnancy in Uzbekistan and Ukraine
  1. Ingrida Platais1,
  2. Tamar Tsereteli1,
  3. Galyna Maystruk2,
  4. Dilfuza Kurbanbekova3,
  5. Beverly Winikoff1
  1. 1 Gynuity Health Projects, New York City, New York, USA
  2. 2 Woman Health & Family Planning Charity Foundation, Kiev, Ukraine
  3. 3 Women’s Wellness Center, Tashkent, Uzbekistan
  1. Correspondence to Ingrida Platais, Gynuity Health Projects, New York City, NY 10017, USA; iplatais{at}


Introduction We aimed to assess the feasibility and acceptability of a second-trimester medical abortion regimen using mifepristone and sublingual misoprostol with no maximum number of misoprostol doses in Uzbekistan and Ukraine.

Methods This prospective open-label study enrolled 306 women with pregnancies of 13–22 weeks in Uzbekistan (n=134) and Ukraine (n=172). Women took 200 mg mifepristone at a place of their choosing, and 24–48 hours later received 400 μg sublingual misoprostol every 3 hours until the expulsion of both fetus and placenta. Study staff interviewed women about the intensity of pain, side effects, and satisfaction with the procedure. The primary outcome was the rate of complete uterine evacuation without surgical intervention or oxytocin at 15 hours after the first dose of misoprostol.

Results The median gestational age was 18.1 weeks, and half of the women (n=149, 48.9%) chose to take mifepristone at home. The majority of women (n=266, 86.9%, 95% CI 82.6% to 90.5%) expelled by 15 hours after the start of misoprostol treatment, and by 48 hours complete uterine evacuation was achieved in 296 (96.7%) women. Most women found pain (76.1%) and side effects (89.0%) to be acceptable or very acceptable, and reported high satisfaction (89.8%) with the procedure.

Conclusion Medical abortion in pregnancies of 13–22 weeks with 200 mg mifepristone followed 24–48 hours later by 400 μg sublingual misoprostol administered every 3 hours until complete expulsion is effective, safe and acceptable to women. Women can be given the option to take mifepristone at home and return to the hospital.

Clinical trials registration number,, NCT02415894, NCT02235155.

  • mifepristone
  • misoprostol
  • second trimester
  • abortion
  • home use

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors IP, TT and BW contributed to study design. IP, TT, GM and DK implemented the study and oversaw data collection. IP and TT led the analysis and writing of the manuscript with input from all authors.

  • Funding Financial support for this study was provided by an anonymous donor without financial interests in the outcome of this study.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by the institutional review board at each study facility in Ukraine and by the ethical review board at the Ministry of Health of the Republic of Uzbekistan.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.